Test bank for claytons basic pharmacology for nurses 19th edition mmupdm pdf

TestvBankvForvClayton’svBasicvPharmacologyvforvNursesv19thvEdition 1




COMPELETE TESTBANK v




TESTBANK FOR CLAYON’S BASIC PHARMACOLOGY F
v v v v v


OR NURSES 19TH EDITION/ WILLIHNGANZ VERIFIEDQU
v v v v v v


ESTIONS AND ANSWERS WITH 2024 UPDATES (ALLCHA
v v v v v v v


PTERS INLUDED 1-48) v v

,TestvBankvForvClayton’svBasicvPharmacologyvforvNursesv19thvEdition 2




Chapter 01: Drug Definitions, Standards, and Information Sources
v v v v v v v v

Willihnganz: Clayton’s Basic Pharmacology for Nurses, 19th Edition
v v v v v v v




1. WhichvnamevidentifiesvavdrugvlistedvbyvthevUSvFoodvDrugv
Administrationv(FDA)?
a. Bran
b. Nonproprietar
c. Official
d. Trademark
ANS:
Thevofficialvnamevisvthevnamevundervwhichvavdrugvisvlistedvbyvth
evFDA.vThevbrandvname,v orvtrademark,visv thev namev givenvtovavd
rugvbyvitsvmanufacturer.vThevnonproprietary,vorvgeneric,vnamevi
svprovidedvbyvthevUnitedvStatesvAdoptedvNamesvCouncil.
CognitivevLevel:vKnowledge REF:v p.v9
OBJ:v1NAT:vNCLEXvClientvNeedsvCategory:vSafe,vEffectivevCarev
EnvironmentvTOP:v NursingvProcessvStep:vAssessment
CON:v
PatientvEducation




2. Whichvsourcevcontainsvinformationvspecificvtovnutritionalvsupplements?
a. USPvDictionaryvofvUSANv &vInternationalvDrugvNames
b. NaturalvMedicinesvComprehensivevDatabase
c. UnitedvStatesvPharmacopoeia/NationalvFormularyv(USPvNF)
d. DrugvInteractionvFacts
ANS:v C
UnitedvStatesvPharmacopoeia/NationalvFormularyvcontainsvinformationvspecificvtovnutritionalvs
upplements.vUSPvDictionaryvofvUSANv&vInternationalvDrugvNamesvisvavcompilationvofvdrugvna
mes,vpronunciationvguide,vandvpossiblevfuturevFDAvapprovedvdrugs;vitvdoesvnotvincludevnutriti
onalvsupplements.vNaturalvMedicinesvComprehensivevDatabasevcontains
evidence-
basedvinformationvonvherbalvmedicinesvandvherbalvcombinationvproducts;vitvdoesvnotvincludevinf
ormationvspecificvtovnutritionalvsupplements.vDrugvInteractionvFactsvcontainsvcomprehensivevi
nformationvonvdrugvinteractionvfacts;vitvdoesvnotvincludevnutritionalvsupplements.

DIF: CognitivevLevel:vKnowledge REF:v p.v4
OBJ:v3vNAT:v NCLEXvClientvNeedsvCategory:vPhysiologicalvIntegr
ity
TOP:v NursingvProcessvStep:vAssessment CON:v Nutritionv|vPatientvEducation

3. Whichvdrugvreferencevcontainsvdrugvmonographsvthatvdescribevallvdrugsvinvavtherapeuticvclass?
a. DrugvFactsvandvComparisons

,TestvBankvForvClayton’svBasicvPharmacologyvforvNursesv19thvEdition 3

b. DrugvInteractionvFacts
c. HandbookvonvInjectablevDrugs
d. Martindale—ThevCompletevDrugvReference

ANS:v A
DrugvFactsvandvComparisonsvcontainsvdrugvmonographsvthatvdescribevallvdrugsvinvavthe
rapeuticvclass.vMonographsvarevformattedvasvtablesvtovallowvcomparisonvofvsimilarvprodu
cts,vbrandvnames,vmanufacturers,vcostvindices,vandvavailablevdosagevformsvOnlinevversi
onvisvavailable.

DIF: CognitivevLevel:vKnowledge REF:v p.v4vTablev1.2
OBJ:vvv 3 NAT:v NCLEXvClientvNeedsvCategory:vPhysiologicalvIntegrity
TOP:v NursingvProcessvStep:vAssessment CON:v Safetyv|vPatientvEducationv|vClinicalvJudgment

4. Whichvdrugvreferencevcontainsvmonographsvaboutvvirtuallyveveryvsingle-
entityvdrugvavailablevinvthevUnitedvStatesvandvdescribesvtherapeuticvusesvofvdrugs,vincludingvap
provedvandvunapprovedvuses?
a. Martindale:vThevCompletevDrugvReference
b. AHFSvDrugvInformation
c. DrugvReference
d. DrugvFactsvandvComparisons
ANS:v B
AHFSvDrugvInformationvcontainsvmonographsvaboutvvirtuallyveveryvsingle-
entityvdrugvavailablevinvthevUnitedvStatesvandvdescribesvtherapeuticvusesvofvdrugs,vincludingvapp
rovedvandvunapprovedvuses.

DIF: CognitivevLevel:vKnowledge REF:v p.v4vTablev1.2
OBJ:vvv 3 NAT:v NCLEXvClientvNeedsvCategory:vPhysiologicalvIntegrity
TOP:v NursingvProcessvStep:vPlanning CON:v Safetyv|vPatientvEducationv|vClinicalvJudgment

5. Whichvonlinevdrugvreferencevmakesvavailablevtovhealthcarevprovidersvandvthevpublicvavstan
dard,vcomprehensive,vup-to-datevlookvupvandvdownloadablevresourcevaboutvmedicines?
a. AmericanvDrugvIndex
b. AmericanvHospitalvFormulary
c. DailyMed
d. DrugvReference
ANS:v C
DailyMedvmakesvavailablevtovhealthcarevprovidersvandvthevpublicvavstandard,vcomprehensive,vu
p-to-
datevlookvupvandvdownloadablevresourcevaboutvmedicines.vThevAmericanvDrugvIndexvisvnotvapp
ropriatevforvpatientvuse.vThevAmericanvHospitalvFormularyvisvnotvappropriatevforvpatientvuse.v
Thevdrugvreferencevisvnotvappropriatevforvpatientvuse.

DIF: CognitivevLevel:vKnowledge REF:v p.v3v|vp.v4
OBJ:v3vNAT:v NCLEXvClientvNeedsvCategory:vPhysiologicalvIntegr
ity
TOP:v NursingvProcessvStep:vImplementation
CON:v Safetyv|vPatientvEducationv|vClinicalvJudgment

6. WhichvlegislationvauthorizesvthevFDAvtovdeterminevthevsafetyvofvavdrugvbeforevitsvmarketing?
a. FederalvFood,vDrug,vandvCosmeticvActv(1938)
b. DurhamvHumphreyvAmendmentv(1952)

, TestvBankvForvClayton’svBasicvPharmacologyvforvNursesv19thvEdition 4

c. ControlledvSubstancesvActv(1970)
d. KefauvervHarrisvDrugvAmendmentv(1962)
ANS:v A
ThevFederalvFood,vDrug,vandvCosmeticvActvofv1938vauthorizedvthevFDAvtovdeterminevthevsafet
yvofvallvdrugsvbeforevmarketing.vLatervamendmentsvandvactsvhelpedvtightenvFDAvcontrolvandven
surevdrugvsafety.vThevDurhamvHumphreyvAmendmentvdefinesvthevkindsvofvdrugsvthatvcannotvb
evusedvsafelyvwithoutvmedicalvsupervisionvandvrestrictsvtheirvsalevtovprescriptionvbyvavlicensedvp
ractitioner.vThevControlledvSubstancesvActvaddressesvonlyvcontrolledvsubstancesvandvtheirvcateg
orization.vThevKefauvervHarrisvDrugvAmendmentvensuresvdrugvefficacyvandvgreatervdrugvsafety.
vDrugvmanufacturersvarevrequiredvtovprovevtovthevFDAvtheveffectiveness vofvtheirvproducts vbefor

evmarketingvthem.

DIF: CognitivevLevel:vKnowledge REF:vp.v5vTablevl.3
OBJ:v 5
NAT:vNCLEXvClientvNeedsvCategory:vPhysiologicalvIntegrityv
TOP:v NursingvProcessvStep:vAssessment
CON:v Safetyv|vPatientvEducationv|vEvidencev|vHealthvCarevLaw

7. Whichvclassificationvdoesvmeperidinev(Demerol)vfallvunder?
a. I
b. II
c. III
d. IV
ANS:v B
Meperidinev(Demerol)visvavSchedulevIIvdrug;vitvhasvavhighvpotentialvforvabusevandvmayvleadvtovse
verevpsychologicalvandvphysicalvdependence.vSchedulevIvdrugsvhavevhighvpotentialvforvabusevand
vnovrecognizedvmedical vuse.vSchedulevIIIvdrugsvhavevsomevpotentialvforvabuse.vUsevmayvleadvto

vlowvtovmoderatevphysicalvdependencevorvhighvpsychological vdependence. vSchedulevIVvdrugsvh

avevlowvpotentialvforvabuse.vUsevmayvleadvtovlimitedvphysicalvorvpsychologicalvdependence.

DIF: CognitivevLevel:vKnowledge REF:v p.v10
OBJ:v2vNAT:v NCLEXvClientvNeedsvCategory:vSafe,vEffectivevCarev
Environment
TOP:v NursingvProcessvStep:vAssessment CON:v PatientvEducationv|vAddictionv|vPain

8. WhichvactionvwouldvthevFDAvtakevtovexpeditevdrugvdevelopmentvandvapprovalvforvanvoutbreakvo
fvsmallpox?
a. Listvsmallpoxvasvavhealthvorphanvdisease.
b. Omitvthevpreclinicalvresearchvphase.
c. Extendvthevclinicalvresearchvphase.
d. Fastvtrackvthevinvestigationalvdrug.
ANS:v D
OncevthevInvestigationalvNewvDrugvApplicationvhasvbeenvapproved,vthevdrugvcanvreceivevhigh
estvpriorityvwithinvthevagency,vwhichvisvcalledvfastvtracking.vAvsmallpoxvoutbreakvwouldvbeco
mevavpriorityvconcernvinvthevworld.vOrphanvdiseasesvarevnotvresearchedvinvavpriorityvmanner.vPr
eclinicalvresearchvisvnotvomitted.vExtendingvanyvphasevofvthevresearchvwouldvmeanvavlongervtim
evtovdevelopvavvaccine.vThevFDAvmustvensurevthatvallvphasesvofvthevpreclinicalvandvclinicalvresea
rchvphasevhavevbeenvcompletedvinvavsafevmanner.

DIF: CognitivevLevel:vKnowledge REF:v p.v7 OBJ:v 5